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The serum concentration of the advanced glycation end-product
N-(carboxymethyl)lysine is increased in uremia. Advanced glycation end
products (AGEs) such as pentosidine and N-(carboxymethyl)lysine
(CML) have been traditionally quantified by HPLC or gas chromatogra-
phy—mass spectrometly (GC/MS). Enzyme-linked immunosorbent assays(ELISA) have been introduced as a convenient alternative to simplify the
detection and measurement of AGEs in proteins and tissues, but some of
these studies are limited by the lack of information on the structure of the
epitopes recognized by antibodies to AGE-proteins. In this work we
demonstrate that an antibody used in a previous study, reporting increased
levels of AGEs in patients with diabetes or on continuous ambulatory
peritoneal dialysis (CAPD) and hemodialysis (HD), recognizes CML as its
major epitope. We also show that there is a significant correlation between
the concentration of AGEs in serum measured by ELISA and a GC/MS
assay for CML in serum proteins. Both analyses yielded comparable
results, with patients on CAPD and HD having about threefold higher
AGE- or CML-concentrations in their serum. Our data suggest that
ELISA assays for CML should be useful for the clinical measurement of
AGEs in serum proteins.
Advanced glycation end-products (AGEs) are formed following
glycation of protein during the Maillard reaction and are impli-
cated in the development of long-term, chronic complications of
diabetes [1, 21, atherosclerosis [3], hemodialysis-associated amy-
loidosis [4, 5] and neurodegenerative diseases [6, 7; reviewed in 81.
AGEs such as pentosidine [9, 10] and N-(carboxymethyl)lysine
(CML) [11, 12] have been traditionally quantified by sophisticated
instrumental techniques, such as reversed phase HPLC with
fluorescence detection or selected ion monitoring gas chromatog-
raphy—mass spectrometry (SIM-GC/MS), methods that are not
readily applied to large numbers of samples in a clinical laboratory
setting. During the last few years immunological techniques have
been introduced to simplify the detection and measurement of
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AGEs in proteins, including immunohistochemical detection of
AGEs in renal basement membrane [13], in Alzheimer's plaque in
brain [6], in amyloid deposits in hemodialysis patients [4], and in
0
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CML
atherosclerotic plaque [14], and ELISA assays for quantifying
AGEs in lens proteins [15], serum proteins [16—18] and skin
collagen [19, 20]. One limitation of these studies is that the
epitope recognized by the antibodies was unknown at the time the
studies were published, and, in some cases, is still unknown [17,
20]. Reddy et al [21] reported, however, that the glycoxidation
product CML was a major epitope recognized by anti-AGE
polyclonal antibodies. Ikeda et al [22] later confirmed the CML
specificity of their monoclonal antibody, 6D12, which had been
used for immunohistochemical detection of AGEs in atheroscle-
rotic plaque [14] and in ELISA assays for quantifying AGEs in
collagen [19] and lens proteins [15]. Fu et al [23] also reported
recently that CML could be formed as a by-product of lipid
peroxidation reactions, suggesting that CML might be a general
biomarker of oxidative stress and oxidative modification of pro-
teins by products of oxidation of both carbohydrates and lipids.
In a recent publication in this journal, some of us [24] have
applied a polyclonal antibody (pDial), prepared against AGE-
proteins to detect and quantify AGEs in serum and, using this
antibody, detected an increase of AGEs in serum of diabetic
patients and in renal failure patients on hemodialysis (HD) and
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Fig. 1. Inhibition of anti-AGE antibody recognition of AGE-RbSA by
CML-BSA (0) and AGE-RbSA (•). Sample concentrations are expressed
in CML equivalents, measured by amino acid analysis. Similar results were
obtained for three other antibody preparations (pDia2, pDia3 and pSRI;
data not shown). Data are expressed as ratios of response with competitor
(B) to controls without competitor (B0).
continuous ambulatory peritoneal dialysis (CAPD). Similar re-
sults were previously reported by Makita et al [17] and Nakayama
et a! [25], but in none of these reports was the specificity of the
antibody known. In the present study we demonstrate that PDial
recognizes CML in serum proteins, and that there is a good
correlation between ELISA and SIM-GC!MS assays for CML in
serum proteins.
METHODS
Materials
N°-(carboxymethyl)lysine (CML)-derivatized bovine serum al-
bumin (CML-BSA) was prepared by reaction of glyoxylic acid
with BSA in the presence of NaBH3CN, as described previously
[21]. AGE-rabbit serum albumin (AGE-RbSA) was prepared by
incubation of rabbit serum albumin with I mol/liter glucose in
phosphate buffer [211. The CML content of the proteins was
determined by amino acid analysis following acid hydrolysis, as
described previously [21]. AGE-RhSA contained 17 mol CML per
mol protein, CML-BSA was modified with 30 mol CML per mol
protein. Polyclonal antibodies pDial, pDia2 and pDia3 were
prepared by immunization of rabbits with AGE- RNase, prepared
by incubating RNase in phosphate buffer containing I mol/liter
glucose for three months at 37°C, as described previously [24].
Serum samples were collected from four control, five CAPD
and five HD patients at the Division of Nephrology (Toronto
Hospital, Western Division), according to standard and approved
procedures. Four of the CAPD and three of the HD patients were
diabetic.
Immunoassay procedures
Competitive ELISA assays were conducted in Costar (Cam-
bridge, MA, USA) multiwell polystyrene plates, coated with 2.5
jig of AGE-RbSA in 0.05 mol/liter carbonate buffer pH 9.6 for
two hours at 37°C [21]. After washing the wells seven times with
phosphate buffered saline (PBS), pH 7.4, containing 0.05% Tween
20, wells were blocked with 300 pA of 1% ovalbumin in PBS-
Tween buffer. In the competition step, 200 pA of the competition
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Fig. 2. AGE and CML concentration in serum of control, CAPD and HD
patients. (A) AGE-content (one AGE-unit is defined as the equivalent to
1 .tg of AGE-BSA) measured by competitive ELISA using time resolved
fluorescence detection [24]. CAPD versus C: P < 0.02; HD versus C: P <
0.03. (B) CML-content measured by SIM-GC/MS [26]. CAPD versus C:
P < 0.0001; HD versus C: P < 0.02. Data are mean so.
mixture of CML-BSA or AGE-RbSA [211 as competitor and a
1:8000 dilution of anti-rabbit antiserum (PDial, 2 or 3; antibodies
were prepared with the same immunization procedure, but in
three different animals) were added to the wells and incubated for
two hours at 37°C. Wells were washed, then incubated with a
1:5000 dilution of horseradish peroxidase-linked goat anti-rabbit
immunoglobulin (Bio-Rad, Hercules, CA, USA) for one hour at
37°C and developed with 200 pA of substrate solution containing
25 mg of 2,2'-azinohis(3-ethylbenzthiazoline-6-sulfonic acid)
(ABTS) (Sigma Chemicals Inc., St. Louis, MO, USA) and 30 jil of
30% hydrogen peroxide per 100 ml 0.1 mol/liter sodium citrate
buffer pH 4.5, as previously described [21]. Absorhance was
measured at 410 nm after approximately 30 minutes of incubation
time.
ELISA assays for the AGE content of serum samples were
conducted as described previously, using Th3-fluorescence for
detection [24].
SIM-GC/MS assays for CML in serum proteins
Serum samples (70 j.tl) were reduced in 500 pi of 100 mmol/liter
sodium horohydride in 0.2 mol/liter sodium borate buffer, pH 9.1,
for four hours at room temperature and dialyzed against deion-
ized water overnight with two water exchanges. The serum
samples were then delipidated by addition of 12 volumes of
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Fig. 3. Correlation between AGE and CML concentrations in serum of
controls, CAPD and HD patients. AGE-ELISA and GC/MS data are from
Figure 1. Symbols are: (0) controls; (U) CAPD; (A) HD patients. Open
symbols indicate samples from non-diabetic patients. The line drawn is a
linear least squares fit to the data (r = 0.75). Pearson Product Moment
non-parametric analysis yielded P < 0.002.
water:methanol:water-saturated diethylether (1:3:8), followed by
centrifugation at 1000 rpm for 15 minutes in a benchtop centri-
fuge. The precipitate was resuspended in 1 ml of water by
vortexing, followed by reprecipitation with methanol/diethylether
(3:8) and centrifugation. After drying of the aqueous phase in
vacuo (Savant Instruments, Farmingdale, NY, USA), internal
standards (17 nmol d8-lysine and 1 nmol d4-CML) were added
and the samples were hydrolyzed for 24 hours in 2 mL of 6
mol/liter HC1 at 110°C. Amino acids were analyzed as trifluoro-
acetyl methyl ester (TFAME) derivatives on an HP series 6980
gas chromatograph—mass spectrometer, as described previously
[261.
Statistical analyses
Data are expressed as mean SD. P values were calculated
using the Student's t-test. Correlation coefficients were deter-
mined by a Pearson Product Moment non-parametrical analysis
using SigmaStat'TM VI.0 for Windows (Jandel Scientific, Ventura,
CA, USA).
RESULTS
To evaluate the antigenic specificity of pDial, used in the
original study, we compared the effectiveness of CML-BSA and
AGE-RbSA as inhibitors of recognition of AGE-RbSA coated on
microtiter plates. As shown in Figure 1, CML-BSA and AGE-
RbSA were equally effective in competing with immobilized
AGE-RbSA, when the proteins were compared on the basis of
their CML content. Half-maximal competition was observed for
both proteins at approximately 0.1 nmol CML-equivalents,
amounting to 3 nmol of CML-BSA and 5.9 nmol of AGE-RbSA,
respectively. At higher concentrations, both proteins fully inhib-
ited recognition of immobilized AGE-RhSA, suggesting specific-
ity of the antibody for the same epitope, CML. Underivatized
proteins yielded less than a 10% decrease in BIB,, at protein
concentrations comparable to those used in the experiments in
Figure 1.
Figure 2 shows the results of analyses of serum proteins from
control, CAPD and HD patients, assayed for their AGE content
by ELISA (Fig. 2A) and CML content by SIM-GC/MS (Fig. 2B)
techniques. By both methods, patients on CAPD or HD have
about threefold higher concentrations of AGEs in their serum,
compared to healthy controls. There was no significant difference
in serum levels of CML by either assay in CAPD, compared to
HD patients. Figure 3 shows that there was a good correlation
between the AGE content of serum proteins measured by the
ELISA and SIM-GC/MS assays.
DISCUSSION
In the present study we have determined that polyclonal
anti-AGE antibody PDial recognizes the epitope CML in AGE-
0.3 proteins (Fig. 1). We have also demonstrated that the AGE
content of serum proteins, measured by an ELISA assay using
PDial antibody, correlates with the CML content of the protein
measured by SIM-GC/MS (Fig. 3), and that by both methods
there are similar, approximately threefold increases in AGEs or
CML in serum proteins from CAPD and HD patients. These data
constitute the first demonstrated correlation between ELJSA and
SIM-GC/MS assays for measurement of CML in serum proteins
and confirm that the specific AGE, CML, is significantly increased
in serum proteins of dialysis patients. Similar results were ob-
tained with three other antibodies (pDia2 and pDia3, unpublished
data; pSR1 [21]), supporting the previous identification of CML
as a major epitope recognized by polyclonal anti-AGE antibodies
[21]. Differences in the avidity with which CML is recognized on
different proteins may explain differences between results of the
ELISA and SIM-GC/MS assays for CML, which are apparent as
deviations from the line corresponding to the least squares fit in
Figure 3.
The identification of CML as the antigen recognized by the
pDia antibodies validates the use of ELISA assays in future
studies on the measurement of serum AGEs. The ELISA proce-
dure is clearly more useful in a clinical setting for assessing the
relationship between AGEs and vascular complications of diabe-
tes and renal disease. However, in our hands, the results obtained
with the ELISA procedure are sensitive to variations in sample
preparation, such as plasma versus serum, EDTA plasma versus
heparin plasma, native versus alkaline treated plasma, and vary
with the type of tissue or fluid used, so that choice of an
appropriate standard and validation of results of ELISA assays by
the SIM-GC/MS are essential for inter-laboratory comparisons.
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APPENDIX
Abbreviations are: AGE, advanced glycation end-product; AGE- RbSA,
AGE-rabbit serum albumin; ABTS, 2,2'-azinobis(3-ethylbenzthiazoline-6-
sulfonic acid); CML-BSA, CML-derivatized bovine serum albumin;
CAPD, continuous ambulatory peritoneal dialysis; HD, hemodialysis;
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CML, N-(carboxymethyl)lysine; SIM-GC/MS, selected ion monitoring
gas chromatography—mass spectrometry.
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